Bonus Presentations
Transthyretin amyloid cardiomyopathy (or ATTR-CM) is a serious, underrecognized, and underdiagnosed cause of heart failure. Through a patient case study and expert perspectives, this program will explore the patient journey for ATTR-CM, including sharing long-term extension data and recently published findings from a real-world study for an oral treatment option for patients with this progressive disease.
Cushing syndrome is characterized by excessive adrenal cortisol secretion, most commonly caused by corticotropin-secreting pituitary adenomas. But did you know that Cushing syndrome disproportionately affects patients with chronic diseases that are potentially mediated by cortisol excess, including type 2 diabetes (T2D) and hypertension? The CATALYST trial found that 24% of patients with difficult-to-control T2D had Cushing syndrome. In other studies, hypertension was found to occur in 80%-85% of patients with Cushing syndrome. In this 30-minute live discussion, experts will discuss what we currently know about the pathogenesis of hypercortisolism and why it is important for physicians to consider Cushing syndrome as a potential cause of difficult-to-control hypertension. Early intervention can help improve the outcomes for these patients. Join us during Medscape’s 5th Annual Going Back to the Heart of Cardiology Conference for this can’t miss expert-to-expert commentary!
Fluid overload in patients with heart failure (HF) and/or chronic kidney disease (CKD) is a common driver of morbidity, mortality, and high healthcare utilization, even in the presence of guideline-directed medical therapy. Diuretics are a mainstay for the treatment of congestion; however, patients are often unresponsive to escalating oral doses and hospitalization to administer intravenous diuretics is met with its own unique challenges. Join our expert faculty as they discuss the unmet treatment needs for patients with edema due to fluid overload, the limitations of traditional diuretic therapy, and how novel subcutaneous loop diuretic delivery systems fit into the treatment pathway to achieve fluid balance and prevent complications.
In this Live Spotlight, our expert faculty will explore the evolving landscape of thrombosis prevention, highlighting patient challenges with current anticoagulation methods and the potential of emerging factor XI inhibitors. Through a patient narrative and expert insights, the session aims to reshape clinical approaches to anticoagulation by integrating cutting-edge research with real-world patient needs.
Despite rigorous implementation and optimal dosing of guideline-directed medical therapy, a subset of patients with heart failure (HF) remain at high residual risk for complications. This vulnerable group of patients may benefit from a multi-modality approach, consisting of treatment options with different mechanisms of action to help prevent hospitalizations and reduce cardiovascular mortality. In this symposium, experts discuss current and emerging treatment options for the prevention and treatment of HF, across a spectrum of ejection fractions.